GlassScriptPhysician profile
Lenda Barrett
NPI 1457965501
$4,110.08
in general payments reported to CMS, 2019-2025
23 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.43 · 2022: $708 · 2023: $883 · 2024: $1,249 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,248 · Education: $94.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,247.78 |
| Education | $94.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $515.29 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $501.91 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $469.63 | 2022-2025 | Farxiga, Breztri |
| Aurinia Pharma U.S., INC. | $393.84 | 2022-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $299.68 | 2021-2025 | Jynarque |
| Travere Therapeutics, INC. | $285.22 | 2022-2025 | Filspari |
| Fresenius USA Marketing, INC. | $270.54 | 2022-2024 | Velphoro |
| Akebia Therapeutics INC | $223.73 | 2021-2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $219.42 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Vifor Pharma, INC. | $182.08 | 2022-2025 | Veltassa |
| Novo Nordisk INC | $134.51 | 2025 | Ozempic |
| Opko Pharmaceuticals, LLC | $101.88 | 2021-2023 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $94.51 | 2022-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $81.08 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.93 | 2023-2024 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $60.00 | 2023 | |
| Apellis Pharmaceuticals, INC. | $55.57 | 2025 | Empaveli |
| Amgen INC. | $42.76 | 2024-2025 | Krystexxa, Tavneos |
| Scpharmaceuticals INC. | $33.85 | 2025 | |
| Baxter Healthcare | $23.93 | 2024 | Renal - Hd |
| Alexion Pharmaceuticals, INC. | $17.70 | 2023 | Ultomiris |
| Ultragenyx Pharmaceutical INC. | $17.24 | 2023 | |
| Daiichi Sankyo INC. | $16.78 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lenda Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.